A study by the Spanish Family and Community Pharmacy Society (SEFAC), conducted with the collaboration of 72 pharmacists in 62 pharmacies of all Spanish autonomous communities and with the participation of 652 patients with diabetes, concludes that only 34% adequately know theirMedication, a percentage that rises in the case of those who have secondary studies (43%) and university (45%).Despite these deficiencies in regard to the knowledge of medication, the number of compliant amounts to 76% of the total.
In total, the number of oral antidiabetic medications detected was 833. In this sense, the study, entitled 'Diabetes in Spain from the perspective of the community pharmacy: knowledge, compliance and satisfaction with treatment', indicates that theMost used active ingredients, alone or associated, were metformin 472 (56.6%), IDPP4 196 (23.5%), sulfonylureas (su) 87 (10.4%) and glin 74 (8.9%).Also, 248 (38.0%) used insulin, of which 97 (39.1%) only insulin and 149 (60.1%) insulin in addition to ado.
SEFAC also offers data on the number of medications used for other pathologies by these patients, with a median 3.0.As an example, they refer to treatment for dilipemia, where, of the 285 patients treated (43.9%), 253 (88.5%) use statins in monkey or bitrapia and 24 (8.4%) fibratas as monotherapy.They also highlight the use of antihypertensives: 177 of the 652 (27.2%) used Araii and 121 (18.6%) IECA.
Regarding satisfaction with treatment, the percentage of patients positive responses was higher among men, 275 (85.9%), than among women, 261 (79.8%), being the global satisfied patients536 (82.8%).In this sense, it should be noted, according to the study "that the compliance presented greater satisfaction than the non -compliant (24.9 ± 6.1 out of 36 points, compared to 23.9 ± 7.9, respectively)", and that "that"Those who use insulin have less satisfaction with the treatment (23.4 ± 6.7) compared to those who do not use it (25.3 ± 6.4).
access to the medical history
Seen some of the main results, SEFAC indicates that "a limitation of the study, which generally affects research in community pharmacy, consists of limited access to the medical history of patients, which makes pathologies and pharmacological treatmentsregistered are those referred to by these, since access to the diagnosis is possible only when the patient, for some circumstance, gives the pharmacist a report in which the figure. "Therefore, they ensure that "access to diagnosis, indicators, objectives, etc. by the community pharmacist, actively involved in the management of the diabetic patient, would significantly result in benefits for their health."